Suppliers / Excella Gmbh

Excella Gmbh

Germany 110 employees 5 duplicate records merged Updated 9 July 2026

Excella Gmbh is an API manufacturer based in Germany. It holds 26 active US drug master files and 23 valid CEPs. Its filings concentrate with MINSA (CR), ARCSA (EC) and INVIMA (CO). Its GMP standing is certified by ZLG (DE), ANVISA (Brazil) and MFDS (Korea), among 6 authorities. Its most recent recorded inspection, by US FDA, closed on 19 October 2022 as VAI.

26
active US DMFs
23
valid CEPs
6
registered plants 1 with an FDA FEI number
51
filings across 7 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
7 of 7 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 19 October 2022 VAI US FDA
  • 12 July 2019 VAI US FDA
  • 17 March 2017 NAI US FDA
  • 29 May 2015 VAI US FDA
  • 17 May 2013 VAI US FDA
  • 10 October 2012 VAI US FDA
  • 12 March 2010 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Feucht, United Arab Emirates Not on file
Feucht, United Arab Emirates Not on file
FEUCHT, Germany Not on file
Feucht, Germany Not on file
Germany, Germany 3000242652
Feucht Germany, Nigeria Not on file

What they file, and where

Molecule Regulators Docs
Methotrexate EDQM, SFDA (Saudi Arabia), US FDA 6
Anastrozole EDQM, SFDA (Saudi Arabia), US FDA 4
Timolol EDQM, SFDA (Saudi Arabia), US FDA 4
Acyclovir EDQM, SFDA (Saudi Arabia), US FDA 3
Deferoxamine SFDA (Saudi Arabia), US FDA 3
Ganciclovir EDQM, US FDA 3
Levothyroxine EDQM, SFDA (Saudi Arabia), US FDA 3
Baclofen EDQM, US FDA 2
Bicalutamide EDQM, US FDA 2
Bupivacaine EDQM, US FDA 2
Show all 30 molecules on file
Haloperidol EDQM, US FDA 2
Masitinib US FDA 2
Ropivacaine SFDA (Saudi Arabia), US FDA 2
Tamoxifen EDQM, US FDA 2
Temozolomide EDQM, US FDA 2
Adapalene US FDA 1
Alfuzosin EDQM 1
Azathioprine EDQM 1
Buspirone US FDA 1
Busulfan EDQM 1
Capecitabine SFDA (Saudi Arabia) 1
Cevimeline US FDA 1
Deferoxamine Mesilate EDQM 1
Dobutamine EDQM 1
Doxazosin US FDA 1
Doxazosin Mesilate EDQM 1
Lanthanum Carbonate US FDA 1
Mianserin EDQM 1
Mycophenolic Acid US FDA 1
Talazoparib SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 20 None
ARCSA (EC) 15 None
INVIMA (CO) 10 None
NCELS (KZ) 2 1
NAFDAC (NG) 2 1
BOMRA (BW) 1 None
ZLG (DE) None 16
ANVISA (Brazil) None 7
MFDS (Korea) None 2
EMA None 2

Comparing suppliers?

Choose your molecules and target markets. Excella Gmbh comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 19 October 2022.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates